Table 1.
Study (Country) | Data Source | Sample Size | Study Period | Cost Calculation Methods | Costs of Surgery, RT, Outpatient Drugs* | Overall Cost* |
---|---|---|---|---|---|---|
Joahnnesen et al17 (Norway)† | National data sources | 171 | 1985-1999 | Estimated primary treatment costs for patients with glioblastoma with three treatment options | Surgery: N/A; RT: $25,618 ($32,665.73); outpatient drugs: N/A | Total average cost per patient: $25,618 ($32,665.73) for RT, $23,442 ($29,891.09) for accelerated RT, $14,534 ($18,532.43) for intracavitary brachytherapy |
Silverstein12 (United States)† | Cost data taken from Rochester Epidemiology Project and Olmstead County Utilization Study; clinical data from chart reviews at the Mayo Clinic | 64 | 1987-1992 | An all-payer perspective was used. Medical charges were used to estimate direct medical costs of treatment. | Surgery: $7,514 ($10,985.67); RT: $9,610 ($14,050); outpatient drugs: N/A | Total cost per patient: $67,887 ($99,252.61) |
Latif15 (United Kingdom)† | Patient data from the Department of Clinical Neurosciences at Western General Hospital, Edinburgh | 236 | 1989-1995 | Median cost per patient was calculated, followed by median cost of each week survival. Amounts calculated using unit costing according to NHS National Costing Project | Surgery: N/A; RT: $28,494 ($40,099.97); outpatient drugs: N/A | N/A |
Mehta38 (United States)† | Computerized billing forms for patients treated at University of Wisconsin | 635 | 1989-1994 | Costing analysis for estimated average costs | Surgery: $13,729-$27,523 for those receiving radiation and surgery ($19,621.95 to $39,336.80); RT: $16,250 ($23,225.05); outpatient drugs: N/A | Average cost per week of survival: $310 ($443.06) for RT, $524 ($748.92) for resection plus radiation, and $270 ($385.89) for radiosurgery plus radiation |
Polinsky et al13 (United States)† | Costs of patients treated in a hospital in Ann Arbor, MI | 29 | 1990-1995 | Average costs calculated for patients undergoing craniotomy or stereotactic craniotomy Cost was calculated by addition of hospital charges | Surgery: N/A; RT: N/A; outpatient drugs: N/A | Average costs for craniotomy: $11,365 ($16,243); stereotactic craniotomy: $8,495 ($12,141.34) |
Blomqvist et al16,45 (Sweden)† | National data sources | Swedish population | 1996 | Nationwide costs of ambulatory, in hospital, long term and palliative/terminal care, drug consumption, temporary and long term morbidity | Surgery: N/A; RT: N/A; outpatient drugs: N/A | Average direct costs of care: $4,599 ($6,445); 71% of the costs, were for short-term hospital care, 19% for long-term hospital-based home care‡ |
Mendez14 (Canada)† | Utilization and clinical data gathered from records of patients treated at Queen Elizabeth II Health Sciences Centre in Nova Scotia | 61 | 1996-1998 | Unit cost data and patient-specific utilization from hospital records | Surgery: $7,957 ($10,306.45); RT combined with surgery: $12,175 ($15,769.89); outpatient drugs: $663 ($858.76) | Average total cost per patient: $11,446 ($14,580); 25% were RT costs, 16% were surgery costs, 7% were chemotherapy costs |
Chang et al6 (United States) | Data source: Insurance claims of 3 million Americans | 652 | 1998-2000 | Cancer costs (seven types of cancer) in a retrospective study | Surgery: $365 ($486) per month, SD, $1,684 ($2,243); RT: $658 ($877) per month, SD, $1436 ($1,913); outpatient drugs: $6 ($8) per month, SD, $38 ($51) | Mean total direct medical costs per patient per month $6,364 ($8,478) |
Kutikova39 (United States) | Data source: MarketScan commercial claims and encounters and Medicare Supplemental and Medicare supplemental and Coordination of Benefits databases | 653 | 1998-2000 | Resource utilization and direct costs were summarized as monthly means and the total amount over the follow-up period | Surgery: N/A; RT: $645 ($713.59) per month outpatient; outpatient drugs: $249 ($275.48) per month | Total cost per patient $49,242 ($54,478.69) |
Mabasa22 (Canada) | Prospective patient cost data; medical records for those in treatment in Canada | 41 | 2001-2002 | Overall survival, duration of therapy, drug cost, labor and supplies, and successive or prior chemotherapy | Surgery: N/A; RT: N/A; outpatient drugs: TMZ $7,430 ($8,454.28); lomustine $98 ($111.51) | Total cost per life-year gained: $32,247 ($36,692.48) to $162,186 ($184,544.50) |
Abbreviations: N/A, not applicable; NHS, National Health Service; RT, radiotherapy; SD, standard deviation; TMZ, temozolomide
Values in parentheses represent 2012 inflation-adjusted costs in dollars.
Studies were conducted before TMZ received FDA marketing approval in the United States (August 1999), Medicines Control Agency approval in the United Kingdom (January 1999), and Health Canada approval (1999).
We estimated the prevalence/incidence and per-person cost of brain cancer in 1997 using data from data provided by Blumqvst and the Swedish government.45